At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We ...

Global vaccine stocks in focus as the U.S. government plans to phase out investment for mRNA vaccine development activities.

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.

George Tidmarsh takes over temporarily at CBER following Vinay Prasad’s abrupt departure; Replimmune trial leaders protest ...